CJC-1295 No DAC + Ipamorelin (10 mg) — Image courtesy of White Market Peptides

At a Glance

CJC-1295 No DAC + Ipamorelin is a pre-blended lyophilised peptide combining 5 mg Modified GRF 1-29 (CJC-1295 No DAC) with 5 mg ipamorelin in a single 10 mg vial. The two act on distinct receptors in the same GH axis: GHRH-R via cAMP and GHS-R1a via calcium. The result is synergistic GH release that exceeds either peptide alone.[1]

Reconstitute: Add 3.0 mL bacteriostatic water → 3.33 mg/mL total (1.67 mg/mL per component).
Standard dose: Titrate from 100 mcg each (200 mcg total) up to a target of 250–300 mcg each (500–600 mcg total) subcutaneous, once daily. Pre-sleep injection is standard.
Easy measuring: At 3.33 mg/mL total on a U-100 syringe, 1 unit = 0.01 mL = 33.3 mcg total (16.7 mcg per peptide). A 100 mcg-each dose (200 mcg total) = 6 units / 0.06 mL.
Storage: Lyophilised: refrigerate at 2–8 °C (freeze at −20 °C for long-term); reconstituted: refrigerate at 2–8 °C; use within 4 weeks.

Overview

Composition: 5 mg CJC-1295 No DAC (Modified GRF 1-29) + 5 mg ipamorelin per 10 mg lyophilised vial.
Goal: Synergistic stimulation of endogenous pulsatile GH release via dual receptor engagement on pituitary somatotrophs.[1]
Schedule: Once-daily subcutaneous injection, on an empty stomach. Pre-sleep is the most common timing.
Dose range: 100–300 mcg per peptide (200–600 mcg total) per injection, titrated upward over the cycle.
Reconstitution: 3.0 mL BAC water per 10 mg vial → 3.33 mg/mL total.
Injection site: Abdomen, thigh, or upper arm; rotate daily.

What You'll Need

Plan based on a representative 12-week titrated cycle, once daily (84 injections, ~33.6 mg total across the escalating schedule).

CJC-1295 No DAC + Ipamorelin Vials (10 mg each): ~33.6 mg needed ÷ 10 mg per vial → 4 vials (40 mg covers the cycle with buffer).
Insulin Syringes (U-100, 0.3 mL / 30-unit preferred): 84 injections → 84 syringes.
Bacteriostatic Water (10 mL bottles): 3.0 mL per vial × 4 vials = 12 mL → 2 × 10 mL bottles.
Alcohol Swabs: 2 per injection → 168 swabs per 12-week cycle.

How to Reconstitute

Allow the refrigerated lyophilised vial to reach room temperature (10–15 minutes).
Draw 3.0 mL bacteriostatic water with a sterile syringe.
Inject slowly down the inner vial wall; do not spray directly onto the powder.
Gently swirl or roll until fully dissolved. Do not shake. Solution should be clear and colourless.
Label with reconstitution date and both component names; refrigerate at 2–8 °C. Use within 4 weeks.

Dosing Schedule

Phase	Dose (each)	Total Dose	Units (U-100)	Volume	Frequency
Weeks 1–2	100 mcg	200 mcg	6 units	0.06 mL	Once daily
Weeks 3–4	150 mcg	300 mcg	9 units	0.09 mL	Once daily
Weeks 5–6	200 mcg	400 mcg	12 units	0.12 mL	Once daily
Weeks 7–12	250–300 mcg	500–600 mcg	15–18 units	0.15–0.18 mL	Once daily

Start at 100 mcg per peptide and increase by ~50 mcg each every 1–2 weeks as tolerated, targeting 250–300 mcg per peptide by weeks 7–12. Administer on an empty stomach; insulin from a recent meal suppresses GH secretion. Pre-sleep timing captures the nocturnal GH window. At the 600 mcg total peak (300 mcg each, 18 units once daily) one 10 mg vial provides ~16 days; at the 200 mcg total starting dose, 50 days.[1]

Protocol Details

Weeks 1–2 (start): 100 mcg each (200 mcg total, 6 units / 0.06 mL) once daily in the evening.
Weeks 3–4: 150 mcg each (300 mcg total, 9 units / 0.09 mL) once daily.[1]
Weeks 5–6: 200 mcg each (400 mcg total, 12 units / 0.12 mL) once daily.
Weeks 7–12 (target): 250–300 mcg each (500–600 mcg total, 15–18 units / 0.15–0.18 mL) once daily.
Cycle length: 8–12 weeks on, with optional extension to 16 weeks. A 4-week off period afterward is a pep-dose recommendation (not from the source protocol) to support receptor sensitivity recovery.
Injection site: Abdomen, thigh, or upper arm; rotate daily to minimise site reactions.

Storage

Lyophilised: Refrigerate at 2–8 °C (35–46 °F); freeze at −20 °C for storage beyond 3 months. Protect from light.
Reconstituted: Refrigerate at 2–8 °C. Avoid freeze-thaw cycles. Use within 4 weeks.
Appearance: Clear, colourless solution. Discard if cloudy, coloured, or particulate.

How CJC-1295 No DAC + Ipamorelin Works

The two peptides act at different receptors on the same pituitary cell.

CJC-1295 No DAC (Modified GRF 1-29) is a 29-amino acid analogue of endogenous GHRH with four substitutions (D-Ala², Gln⁸, Ala¹⁵, Leu²⁷) that confer resistance to DPP-IV cleavage.[2] It binds the GHRH receptor (GHRH-R) on pituitary somatotrophs, activating Gs/adenylyl cyclase/cAMP/PKA to drive GH synthesis and release. Half-life: ~30 minutes, a clean pulse aligned with natural pulsatility, without the prolonged albumin-binding extension of the DAC form. CAS 863288-34-0. MW 3367.95.

Ipamorelin binds GHS-R1a (the ghrelin receptor) on the same cells, coupling through Gαq → PLC → IP₃ → calcium release to trigger a separate secretory cascade.[3] CAS 170851-70-4. MW 711.85.

When both act simultaneously, the cAMP signal from GHRH-R and the calcium signal from GHS-R1a converge as mutually reinforcing secretory inputs. The result is a GH pulse larger than either peptide produces alone.[1]

Good to Know

Both peptides have a half-life of ~30 minutes. Timing relative to sleep and fasting matters more than with longer-acting analogues.
CJC-1295 No DAC (Modified GRF 1-29) is a distinct compound from CJC-1295 with DAC. The DAC cysteine modification binds albumin and extends half-life to 6–8 days, a fundamentally different pharmacokinetic profile. This vial contains the No-DAC form only.
Administer on an empty stomach; insulin suppresses the GH pulse.
WADA status: Both peptides are S2-class non-approved peptides. Athletes under anti-doping programmes must not use this blend.
For background on the mechanism, evidence, and research applications, see What Is CJC-1295 + Ipamorelin Blend?.

Tips for Best Results

Inject on an empty stomach, at least 1–2 hours after the last meal. Pre-sleep is the primary timing in most research protocols.
Injecting once daily on an empty stomach, fasted before bed or on waking, keeps the GH pulse aligned with natural pulsatility.
Pair with adequate protein (1.2–1.6 g/kg) and consistent sleep (7–9 hours); GH/IGF-1 elevation works in concert with recovery.
Avoid eating for 30–60 minutes post-injection.
Track injection sites and rotate; note any local reactions on the first few injections.

Injection Tips

Clean the vial stopper and injection site with separate alcohol swabs; allow both to air-dry fully before proceeding.
Using a 29–31 gauge insulin syringe (5/16″ to 1/2″ needle), draw the calculated dose precisely.
Pinch a fold of skin and insert the needle at 45° into subcutaneous fat (90° is acceptable with a short needle into a well-pinched fold).
Inject slowly over 2–3 seconds; do not aspirate. Withdraw the needle, apply gentle pressure, and do not rub the site.
Rotate injection sites (abdomen, thighs, upper arms) and dispose of each syringe in a sharps container immediately after use.[4]

CJC-1295 No DAC + Ipamorelin (10 mg)